A double-blinded RCT in 162 adults found wound blotting-guided biofilm management improved the DMIST wound score and biofilm removal over three weeks in diabetic foot ulcers, though only surrogate endpoints were measured. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
A single-centre randomised controlled trial testing multidisciplinary multifactorial care against standard care in 192 adults with type 2 diabetes, with a modest HbA1c reduction and improved eGFR. PICO summary and expert commentary.
A MEAD post-hoc analysis finds the dexamethasone implant doubles diabetic macular oedema resolution, with thicker baseline maculae resolving more slowly. PICO summary and commentary.
A phase IV randomized trial in 90 adults with type 2 diabetes found dapagliflozin plus exenatide augmented beta-cell function and insulin sensitivity above either agent alone, on surrogate OGTT measures. PICO summary and expert commentary.
A crossover trial finds orange juice with breakfast raises glucose no more than whole orange or a sugary drink of matched sugar in well-controlled type 2 diabetes. PICO summary and commentary.
An ACCORD analysis finds a triglyceride-glucose-waist index independently predicts cardiovascular events and mortality in type 2 diabetes, beating TyG alone. PICO summary and commentary.
A four-arm community trial finds integrated diabetes-and-periodontitis self-management improves glycaemic control and oral health more than single-disease care. PICO summary and commentary.
A controlled study finds adding vildagliptin to premixed insulin reduces glycaemic variability and improves time in range in type 2 diabetes. PICO summary and commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.
An EXSCEL mediation analysis finds conventional risk-factor changes explain only part of exenatide’s cardiovascular benefit and do not mediate its mortality effect. PICO summary and commentary.